Ironwood Pharmaceuticals
(NASDAQ) IRWD
Ironwood Pharmaceuticals Financials at a Glance
Market Cap
$768.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$361.51M
Net Income (TTM)
$102.18M
EPS (TTM)
$0.60
P/E Ratio
7.82
Dividend
$0.00
Beta (Volatility)
0.68 (Low)
Dividend
$0.00
Beta (Volatility)
0.68 (Low)
Price
$4.49
Volume
91,807
Open
$4.62
Price
$4.49
Volume
91,807
Open
$4.62
Previous Close
$4.49
Daily Range
$4.38 - $4.62
52-Week Range
$0.67 - $5.78
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
0.68 (Low)
Price
$4.49
Volume
91,807
Open
$4.62
Previous Close
$4.49
Daily Range
$4.38 - $4.62
52-Week Range
$0.67 - $5.78
Estimated Earnings Date
Aug 6, 2026
IRWD News
3 Great Stocks Under $10
IRWD: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Ironwood Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
100
CEO
Thomas A. McCourt
Website
www.ironwoodpharma.comHeadquarters
Boston, MA 02110, US
IRWD Financials
Key Financial Metrics (TTM)
Gross Margin
99.62%
Operating Margin
55.83%
Net Income Margin
28.26%
Return on Equity
-38.88%
Return on Capital
35.35%
Return on Assets
23.51%
Earnings Yield
12.79%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$768.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
164.61M
Volume
91.81K
Avg. Volume
2.46M
Financials (TTM)
Gross Profit
$360.13M
Operating Income
$201.84M
EBITDA
$207.13M
Operating Cash Flow
$112.21M
Capital Expenditure
-$3.00K
Free Cash Flow
$112.21M
Cash & ST Invst.
$220.47M
Total Debt
$597.36M
Ironwood Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$106.51M
+158.9%
Gross Profit
$106.06M
+673.6%
Gross Margin
99.58%
N/A
Market Cap
$768.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$7.69M
N/A
Employees
100
N/A
Net Income
$40.77M
+209.1%
EBITDA
$74.76M
+842.4%
Quarterly Fundamentals
Total Cash
$220.47M
+103.2%
Total Debt
$597.36M
-0.3%
Accounts Receivable
$105.84M
+166.1%
Inventory
$0.00
N/A
Long Term Debt
$394.23M
-33.8%
Short Term Debt
$203.12M
+6239.7%
Return on Assets
23.51%
N/A
Return on Invested Capital
1.02%
N/A
Free Cash Flow
$5.12M
-74.3%
Operating Cash Flow
$5.12M
-74.3%